David Brooks is Hartnett Professor of Neurology in the Department of Medicine, Imperial College, London. His research involves the use of positron emission tomography and magnetic resonance imaging to diagnose and study the progression of Alzheimer’s and Parkinson’s diseases in life and to validate imaging biomarkers for therapeutic trials. To date, he has published over 350 reports in peer reviewed journals, including Nature and has an h index of 97. His research is supported by grants from the EU FP7 programmes, UK Medical Research Council, the Alzheimer’s Research Trust, Parkinson’s UK, the Michael J Fox Foundation, Lundbeck Foundation, Danish Council for Independent Research, and industry. He is Chairman of the Executive Committee of the EMBL Nordic Hub at Aarhus University and is a member of the scientific advisory board of Alzheimer UK. He has been a member of the scientific advisory boards of the German Dementia and Parkinson networks, the Austrian KLIF Science Fund, the Research Advisory Panels of the UK Parkinson’s Disease Society, Inserm, the Michael J. Fox Foundation (2002-2006), UK Medical Research Council Neuroscience and Mental Health Board (2004-2007), UK Huntington’s Disease Association, and was Chairman of the Scientific Issues Committee of the Movement Disorder Society (1998-2002) and a Director of the International Society of Cerebral Blood Flow and Metabolism (1993-1997). He was Chairman of the Council of Management of the UK Parkinson’s Disease Society 1997-8.
He is an Associate Editor of Brain and on the Editorial Boards of Parkinsonism and Related Disorders, Basal Ganglia, Journal of Parkinson's Disease, Clinical Neurology and Neurosurgery, Synapse, Molecular Imaging and Biology, Journal of Neurotherapeutics, and Current Trends in Neurology. He was on the editorial boards of the Journal of Neural Transmission, Journal of Neurology, Neurosurgery, and Psychiatry and Movement Disorders.
In 2001 he was elected a Fellow of the Academy of Medical Science, UK. In 2002 he was invited to give the Stan Fahn Lecture at the International Congress of Movement Disorders, Miami, in 2003 the George Cotzias Lecture in Madrid, in 2004 the Charles E Wilson Lecture, the Psychobiology Institute, Jerusalem March 2004, in 2005 the Kuhl-Lassen lecture at the Society of Nuclear Medicine, Toronto, and in 2006 the Sprague lecture at UC Irvine.
et al., 2019, Progressive loss of raphe nuclei serotonin transporter in early Parkinson's disease: A longitudinal 123I-FP-CIT SPECT study., Parkinsonism Relat Disord
et al., 2019, Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study)., Trials, Vol:20
et al., 2019, Widespread microglial activation in multiple system atrophy, Movement Disorders, Vol:34, ISSN:0885-3185, Pages:564-568
et al., 2019, Microglial activation in early Alzheimer trajectory is associated with higher gray matter volume, Neurology, Vol:92, ISSN:0028-3878, Pages:E1331-E1343
et al., 2019, Dynamic 11C-PiB PET shows cerebrospinal fluid flow alterations in Alzheimer's disease and multiple sclerosis., J Nucl Med